Your browser is no longer supported. Please, upgrade your browser.
Settings
PGEN Precigen, Inc. daily Stock Chart
PGEN [NASD]
Precigen, Inc.
Index- P/E- EPS (ttm)-1.13 Insider Own1.40% Shs Outstand160.34M Perf Week-6.02%
Market Cap763.44M Forward P/E- EPS next Y-0.54 Insider Trans-15.04% Shs Float143.87M Perf Month3.42%
Income-175.40M PEG- EPS next Q-0.14 Inst Own74.70% Short Float21.92% Perf Quarter55.67%
Sales97.20M P/S7.85 EPS this Y57.60% Inst Trans3.11% Short Ratio15.07 Perf Half Y-28.10%
Book/sh0.54 P/B8.39 EPS next Y10.00% ROA-59.90% Target Price- Perf Year-41.55%
Cash/sh0.88 P/C5.12 EPS next 5Y2.40% ROE-190.60% 52W Range1.26 - 8.70 Perf YTD-17.34%
Dividend- P/FCF- EPS past 5Y-10.10% ROI-69.70% 52W High-47.93% Beta1.70
Dividend %- Quick Ratio2.50 Sales past 5Y4.80% Gross Margin38.70% 52W Low259.52% ATR0.53
Employees770 Current Ratio2.70 Sales Q/Q31.90% Oper. Margin- RSI (14)52.93 Volatility7.70% 10.92%
OptionableYes Debt/Eq2.54 EPS Q/Q44.50% Profit Margin- Rel Volume0.47 Prev Close4.32
ShortableYes LT Debt/Eq2.16 EarningsMay 06 AMC Payout- Avg Volume2.09M Price4.53
Recom2.30 SMA20-2.24% SMA5023.55% SMA2000.95% Volume984,549 Change4.86%
May-08-20Initiated H.C. Wainwright Buy $5
Jun-22-20 08:45AM  
Jun-11-20 07:30AM  
Jun-10-20 09:35AM  
Jun-04-20 04:05PM  
May-21-20 02:27PM  
May-15-20 07:30AM  
Apr-29-20 07:30AM  
Apr-20-20 07:36AM  
Mar-02-20 04:05PM  
Feb-24-20 07:30AM  
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; proprietary methane bioconversion platform that turns natural gas into energy and chemical products; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and L. lactis is a food-grade bacterium. Additionally, it provides RheoSwitch inducible gene switch that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with ZIOPHARM Oncology, Inc.; Ares Trading S.A.; Oragenics, Inc.; Intrexon T1D Partners, LLC; Intrexon Energy Partners, LLC; Intrexon Energy Partners II, LLC; Fibrocell Science, Inc.; OvaXon, LLC; S & I Ophthalmic, LLC; Harvest start-up entities; and Surterra Holdings, Inc. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is based in Germantown, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Frank StevenDirectorJun 30Option Exercise3.172,9689,409265,563Jul 06 04:22 PM
ALVAREZ CESAR LDirectorJun 23Option Exercise3.172,9689,409184,133Jun 25 04:22 PM
MITCHELL DEAN JDirectorJun 19Option Exercise3.172,9689,409105,441Jun 23 04:57 PM
Lehr Donald P.Chief Legal OfficerJun 16Sale4.508,42837,926231,558Jun 17 04:35 PM
Perez Jeffrey ThomasSVP, IP AffairsJun 16Sale4.507,61934,286225,889Jun 17 04:32 PM
Sterling Rick L.Chief Financial OfficerJun 16Sale4.507,61934,286287,973Jun 17 04:32 PM
Lehr Donald P.Chief Legal OfficerMay 18Sale2.3662,895148,659214,986May 19 04:33 PM
Sterling Rick L.Chief Financial OfficerMay 18Sale2.3656,853134,372270,592May 19 04:34 PM
Perez Jeffrey ThomasSVP, IP AffairsMay 18Sale2.3656,853134,372208,508May 19 04:33 PM
Sabzevari HelenPresident and CEOMay 15Sale2.37217,527515,800389,365May 18 04:04 PM